Newsroom & Stories

NEWSROOM

News & Stories

Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer
By Ryan Scott June 1, 2024 Key Takeaways Patients with MammaPrint high-2, BluePrint Luminal B, HR-positive, HER2-negative early breast cancer had better 3-year RFS with anthracycline plus a taxane Read More
Improved RFS Seen with Anthracycline Plus Chemo in MP High-2–Risk, HR+/HER2– Early Breast Cancer
By Ryan Scott June 1, 2024 A lower risk of disease recurrence was seen when combining anthracycline and chemotherapy to treat certain patients with breast cancer. Anthracycline plus a taxane Read More
Coffee with America: Dr. William Audeh for Agendia Breast Cancer Subtyping
Discover why understanding the specific characteristics of breast cancer is crucial for developing personalized treatment strategies that can significantly improve outcomes. Dr. William Audeh, a leading medical oncologist specializing Read More

Newsroom

Press Releases

MammaPrint® approved for Reimbursement in the Netherlands

Karen Guzdzial2024-08-05T13:55:30-07:00

The Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect.

Read More

Agendia® Names Joyce A. O’Shaughnessy, MD as New Principal Investigator for FLEX Study

Karen Guzdzial2024-08-05T12:29:06-07:00

Renowned breast oncologist and clinical researcher to lead ongoing efforts to accelerate diagnostic discoveries and enable precision oncology through real-world evidence-based study platform

Read More

New Neoadjuvant Trial (MINT) Confirms the Predictive Utility of MammaPrint + BluePrint

Karen Guzdzial2023-09-28T06:05:31-07:00

The newly published prospective Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia’s advanced genomic assays.

Read More